Bifogade filer
PDF
Kurs
+1,50%
Likviditet
0,23 MSEK
Kalender
| Tid* | ||
| 2025-06-03 | 07:00 | Bokslutskommuniké 2025 |
| 2025-03-03 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-01-20 | N/A | Extra Bolagsstämma 2025 |
| 2024-12-04 | - | Kvartalsrapport 2025-Q2 |
| 2024-09-26 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2024-09-25 | - | Årsstämma |
| 2024-08-29 | - | Kvartalsrapport 2025-Q1 |
| 2024-05-30 | - | Bokslutskommuniké 2024 |
| 2024-02-29 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-04 | - | Kvartalsrapport 2024-Q2 |
| 2023-10-04 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2023-09-27 | - | Årsstämma |
| 2023-08-31 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-08 | - | Bokslutskommuniké 2023 |
| 2023-03-01 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-01 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-03 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2022-09-28 | - | Årsstämma |
| 2022-08-31 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-10 | - | Bokslutskommuniké 2022 |
| 2022-03-02 | - | Kvartalsrapport 2022-Q3 |
| 2021-12-02 | - | Kvartalsrapport 2022-Q2 |
| 2021-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2021-09-02 | - | Kvartalsrapport 2022-Q1 |
| 2021-05-31 | - | Bokslutskommuniké 2021 |
| 2021-03-03 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-02 | - | Kvartalsrapport 2021-Q2 |
| 2020-09-30 | - | Årsstämma |
| 2020-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2020-08-24 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-08 | - | Bokslutskommuniké 2020 |
| 2020-04-20 | - | Extra Bolagsstämma 2020 |
| 2020-03-02 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-02 | - | Kvartalsrapport 2020-Q2 |
| 2019-09-30 | - | Årsstämma |
| 2019-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2019-09-02 | - | Kvartalsrapport 2020-Q1 |
| 2019-06-10 | - | Bokslutskommuniké 2019 |
| 2019-03-04 | - | Kvartalsrapport 2019-Q3 |
| 2018-12-17 | - | Kvartalsrapport 2019-Q2 |
| 2018-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2018-09-24 | - | Årsstämma |
| 2018-09-24 | - | Kvartalsrapport 2019-Q1 |
| 2018-06-25 | - | Bokslutskommuniké 2018 |
| 2018-03-26 | - | Kvartalsrapport 2018-Q3 |
| 2017-12-18 | - | Kvartalsrapport 2018-Q2 |
| 2017-09-25 | - | Årsstämma |
| 2017-09-25 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-30 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA implant system to amputees, announces that Ty Hanners has been appointed Director of Sales, US, focused on expanding the OPRA surgical system product offering to amputees. He will start on October 14, 2024.
Ty Hanners is a results-oriented sales leader with over 20 years in the prosthetic and orthopedic implant industry. He most recently served as a sales leader at Willowood Inc. and has past experience at Össur and Xtremity, innovative prosthetic and medical companies. Ty will be focused on business development, patient capture, and organizational transformation.
"We are thrilled to welcome Ty Hanners to the Integrum team. Ty's leadership and past successes will provide immediate contributions to our expanding products and commercial strategy. Ty is a results-oriented leader with a deep understanding of the industry. He has helped to develop breakthrough healthcare technologies and has experience within the O&P market," comments Jeffrey Zanni, US President, Integrum.
"I'm very impressed by the Integrum portfolio, their approved technologies, and continued innovation in improving life for amputees. I'm excited for this opportunity to manage the US Sales team and drive the success of Integrum," comments Ty Hanners, National Director of Sales, US, Integrum.
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.